Novartis Drug Pricing Agreement

Novartis reached a drug pricing agreement with the US government that lowers prices for innovative medicines, while the firm will launch future drugs at comparable prices across high-income countries. Novartis also introduces direct-to-patient platforms for Mayzent, Rydapt, and Tabrecta via TrumpRx, and it applies to the GENEROUS model for Medicaid access. In exchange, the company gets three years of tariff relief, as Novartis commits to major US investments that include a $1.1 billion San Diego research hub, along with a North Carolina manufacturing hub and expanded radioligand therapy facilities. This forms part of a $23 billion five-year expansion, and CEO Vas Narasimhan stressed partnership for innovation and patient access.

The Novartis drug pricing agreement aligns voluntary pricing with US priorities by tackling drug costs without changes to existing portfolios, as Novartis enhances US-based R&D and manufacturing to build supply chain resilience and local jobs. Coast-to-coast facilities span New Jersey to California, positioning Novartis to prioritize innovation-valued markets, while the deal addresses global pharma investment imbalances.

US drug prices are among the highest globally with Americans pay more. CMS reported Medicare Part D spending over $200 billion yearly in 2024, and policies like the Inflation Reduction Act (IRA) set price caps on high-cost drugs from 2026. Novartis’s steps go beyond the IRA by covering non-Medicare channels like TrumpRx, while HHS model tests aim to boost Medicaid access and support the GENEROUS model.

This could cut out-of-pocket costs and boost access for rare disease treatments, as Mayzent treats multiple sclerosis, Rydapt treats AML, and Tabrecta treats lung cancer. Healthcare spending for these may drop 10-20%. Yet uniform pricing might squeeze margins and hit R&D unless volume rises. For more, visit Novartis’s announcement.